BIO Stock Analysis: Buy, Sell, or Hold?
BIO - Bio-Rad Laboratories, Inc.Class A
$279.99
1.63 (0.59%)
▲
5d:
+1.25%
30d:
-1.65%
90d:
-7.59%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Accumulation
BIO is down 6.1% this week, but smart money is accumulating calls. Top strike: $290 2026-04-17 with 5 OI. Call ratio: 91% View Scanner →
Strength: 7.1/10
Get Alerted When BIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BIO shows positive signals but monitor for confirmation. Market pricing in 3.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: BIO shows positive signals but monitor for confirmation. Market pricing in 3.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$406.33
Based on 7.5% avg growth
INTRINSIC VALUE TODAY
$252.30
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIO is currently trading at $279.99, which is considered extended relative to its 30-day fair value range of $265.35 to $278.04. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.7) compared to its historical average (27.7). Remarkably, the market is currently pricing in an annual earnings decline of 3.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BIO is in a strong downtrend. The price is approaching resistance at $284.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BIO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $321.25 (+14.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BIO is in a strong downtrend. The price is approaching resistance at $284.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BIO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $321.25 (+14.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$265.35 -
$278.04
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
67.3%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($321.25)
Fair Price Analysis
30-Day Fair Range
$265.35 -
$278.04
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$19.03
(6.8%)
Support & Resistance Levels
Support Level
$260.59
Resistance Level
$284.45
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.70
Wall Street Target
$321.25
(+14.7%)
Revenue Growth (YoY)
3.9%
Earnings Growth (YoY)
-83.0%
Profit Margin
29.4%
Valuation Discount vs History
-3.7% cheaper
PE vs Historical
24.7 vs 27.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.7%
(market-implied from PE analysis)
1-Year Target
$269.63
(-4%)
2-Year Target
$259.65
(-7%)
3-Year Target
$250.05
(-11%)
3-Yr Target (if PE normalizes)
(PE: 25→28)
$280.43
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.7, Growth: 11.0%)
$382.57
(+37%)
Base:
(SPY PE: 20.6, Growth: 11.0%)
$318.62
(+14%)
Bear:
(PE: 17.5, Growth: 11.0%)
$270.83
(-3%)
📈
Valuation based on Current Earnings
Trailing PE: 9.50 | Current EPS (TTM): $27.85
Bull Case
$145.47
(-45%)
Analyst growth -50.0%, PE expands to 10.5
Base Case
$132.24
(-50%)
Market implied -50.0%, PE stable at 9.5
Bear Case
$179.85
(-32%)
Severe decline -20.0%, PE contracts to 8.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.7 to 27.7
Stabilization Target:
$314.01
(+12.2%)
PE Expansion Potential:
+12.2%
Share & Embed Analysis
Last updated: April 04, 2026 5:12 AM ET
Data refreshes hourly during market hours. Next update: 6:12 AM
Data refreshes hourly during market hours. Next update: 6:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
James Barry
SELL
700 shares
2025-11-06
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 61 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 62 BUY |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$93 | 62 BUY |
|
PEN
Penumbra Inc |
STRONG BUY
18 analysts |
$360 | 58 HOLD |
Advanced BIO Option Strategies
Professional options setups generated by AI based on today's BIO price and gamma walls.
